Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 PIK3CA correlation analysis

From: Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

  PIK3CAmutant PIK3CAwild-type n Pvalue
ER at diagnosis     
   Positive 14 18 32 0.0082
   Negative 1 16 17  
HER2 at diagnosis     
   Positive 2 13 15 0.17
   Negative 12 21 33  
ER at recurrence     
   Positive 13 14 27 0.0076
   Negative 3 21 24  
HER2 at recurrence     
   Positive 1 11 12 0.79
   Negative 14 24 38  
  1. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.